Ozone therapy takes a fundamentally different approach to autoimmune disease than conventional immunosuppressive drugs: instead of shutting down the immune system, it modulates it. This distinction matters. Standard autoimmune treatments like methotrexate, biologics, and corticosteroids work by broadly suppressing immune function, which reduces symptoms but also increases infection risk and comes with significant side effects. Ozone therapy, through oxidative preconditioning, appears to rebalance immune function by shifting the Th1/Th2 cytokine profile and reducing inflammatory mediators without broadly suppressing immunity.1
This guide covers how ozone modulates the immune system, which autoimmune conditions have been studied, the current evidence by condition, safety considerations unique to autoimmune patients, and typical treatment protocols.
Key Takeaways
- Ozone therapy modulates immunity through the Nrf2 pathway and cytokine rebalancing rather than broadly suppressing the immune system1
- Rheumatoid arthritis has the most clinical data among autoimmune conditions, with studies showing reduced joint inflammation and pain scores2
- Multiple sclerosis patients have shown improvements in fatigue and functional capacity in small trials3
- Inflammatory bowel disease (Crohn’s and ulcerative colitis) responds to rectal ozone insufflation, with direct contact reducing intestinal inflammation4
- Ozone therapy can be used alongside most immunosuppressive medications, though coordination with your rheumatologist or immunologist is essential
- Treatment costs range from $150 to $400 per session, with protocols of 15 to 30 sessions
Immune Modulation vs. Immunosuppression
Understanding the difference between modulation and suppression is critical for autoimmune patients evaluating ozone therapy.
Immunosuppression (methotrexate, azathioprine, biologics like Humira) works by reducing overall immune activity. This controls the autoimmune attack but also reduces the body’s ability to fight infections, increases cancer risk over time, and can cause organ toxicity.
Immune modulation (ozone therapy’s proposed mechanism) works by adjusting the balance between pro-inflammatory and anti-inflammatory immune responses. Ozone therapy activates the Nrf2 pathway, which upregulates antioxidant defenses and downregulates NF-kB, a master regulator of inflammatory gene expression.1
The downstream effects include:
- Reduced pro-inflammatory cytokines: TNF-alpha, IL-1beta, and IL-6 decrease after ozone treatment5
- Increased anti-inflammatory cytokines: IL-10 and TGF-beta production increases
- Th1/Th2 rebalancing: Many autoimmune diseases involve excessive Th1 or Th17 activity. Ozone appears to shift this balance toward a less inflammatory profile
- Regulatory T cell activation: Some evidence suggests ozone promotes regulatory T cell (Treg) function, which helps prevent autoimmune attacks
“The concept of immune modulation through controlled oxidative stress represents a paradigm shift in thinking about autoimmune treatment. Rather than suppressing the entire immune system, the goal is to correct the dysregulation that drives the autoimmune response.” Bocci V, Ozone: A New Medical Drug, Springer, 2011
Evidence by Autoimmune Condition
Rheumatoid Arthritis (RA)
RA has the most clinical data among autoimmune conditions treated with ozone. A 2016 randomized controlled trial by Leon Fernandez et al. enrolled 60 RA patients and compared ozone autohemotherapy plus standard treatment versus standard treatment alone over 12 weeks. The ozone group showed significant reductions in Disease Activity Score (DAS28), C-reactive protein levels, and patient-reported pain scores.2
The mechanism appears to involve both systemic immune modulation (through MAH) and local anti-inflammatory effects when ozone is injected directly into affected joints. Intra-articular ozone injections have been studied for knee osteoarthritis, and the anti-inflammatory principles apply to RA joint inflammation as well.
Multiple Sclerosis (MS)
MS involves immune-mediated destruction of myelin sheaths around nerve fibers. Several small clinical studies have examined ozone therapy in MS patients. A 2013 study by Delgado-Roche et al. treated 30 MS patients with 20 sessions of rectal ozone insufflation and found improvements in fatigue scores and oxidative stress markers.3
Ozone’s potential benefits in MS include reduced neuroinflammation, improved cerebral oxygenation, and enhanced antioxidant capacity in the central nervous system. However, no large-scale randomized trials have been completed, and the evidence remains preliminary.
Inflammatory Bowel Disease (Crohn’s and Ulcerative Colitis)
Rectal ozone insufflation is particularly relevant for IBD because it delivers ozone directly to the inflamed intestinal mucosa. A Cuban research group led by Menendez et al. reported improvements in Crohn’s Disease Activity Index (CDAI) scores in a series of 20 patients treated with rectal insufflation.4
The proposed mechanisms include direct antimicrobial effects on pathogenic gut bacteria, reduction of mucosal inflammation, and improved mucosal blood flow. Ozonated water administered orally has also been studied as a complementary approach.
Systemic Lupus Erythematosus (SLE)
Lupus research with ozone therapy is limited to small case series and clinical observations. The theoretical basis is sound: ozone’s ability to reduce TNF-alpha, modulate complement activation, and improve microcirculation could address multiple aspects of lupus pathology. However, lupus patients are often on complex immunosuppressive regimens, and the interaction between ozone and drugs like mycophenolate or cyclophosphamide has not been systematically studied.
Practitioners who treat lupus patients with ozone generally use low-dose MAH and monitor disease activity closely. Read our detailed guide on ozone therapy for lupus for more on this topic.
Psoriasis and Eczema
Skin-related autoimmune conditions have been treated with both systemic ozone (MAH) and topical approaches (ozonated oils). A case series by Zaky et al. documented improvements in Psoriasis Area and Severity Index (PASI) scores after 12 sessions of MAH combined with topical ozonated olive oil.6
Ozonated oils are well-studied for wound healing and skin conditions. They contain ozonides that release oxygen slowly into the skin, modulating local inflammation. Our guide to ozone therapy for eczema covers this topic in detail.
Evidence Summary Table
| Condition | Evidence Level | Key Findings | Preferred Modality |
|---|---|---|---|
| Rheumatoid Arthritis | Moderate (RCTs exist) | Reduced DAS28, CRP, pain | MAH + intra-articular |
| Multiple Sclerosis | Low-Moderate (small trials) | Improved fatigue, oxidative markers | MAH or rectal insufflation |
| Crohn’s / Ulcerative Colitis | Low-Moderate (case series) | Improved CDAI scores | Rectal insufflation |
| Lupus (SLE) | Low (case reports) | Symptom improvement reported | Low-dose MAH |
| Psoriasis / Eczema | Low (case series) | Improved PASI scores | MAH + ozonated oils |
Safety for Autoimmune Patients
Autoimmune patients have specific safety considerations that do not apply to the general population:
- Drug interactions: Ozone therapy can be used alongside most immunosuppressive medications, but your ozone practitioner and prescribing physician should coordinate. There are no documented dangerous interactions, but clinical experience is limited for some drug combinations.
- Flare risk: Some practitioners report that immune modulation can occasionally trigger a temporary disease flare, particularly in the first few sessions. Starting with lower ozone concentrations and gradually increasing helps minimize this risk.
- G6PD deficiency: This enzyme deficiency, which is more common in certain autoimmune populations, is an absolute contraindication for ozone therapy.
- Active severe flare: Most practitioners recommend waiting until an acute flare is controlled before starting ozone therapy. Beginning treatment during a severe flare may worsen symptoms.
Typical Protocols
| Phase | Frequency | Duration | Concentration |
|---|---|---|---|
| Induction | 2-3x per week | 6-10 weeks | 15-30 mcg/mL (start low) |
| Transition | 1x per week | 4-8 weeks | 25-40 mcg/mL |
| Maintenance | 1x every 2-4 weeks | Ongoing | 25-40 mcg/mL |
Cost for Autoimmune Treatment
| Protocol | Sessions | Total Cost |
|---|---|---|
| MAH induction (15 sessions) | 15 | $3,000-$6,000 |
| Full protocol (25 sessions) | 25 | $5,000-$10,000 |
| Rectal insufflation protocol (20 sessions) | 20 | $1,500-$3,000 |
| Monthly maintenance (12 months) | 12 | $2,400-$4,800 |
Insurance does not cover ozone therapy for autoimmune conditions. Some patients use HSA/FSA funds when their plan allows it for alternative therapies.
The Bottom Line
Ozone therapy offers a mechanistically different approach to autoimmune disease management. Rather than suppressing the immune system, it aims to correct the dysregulation that drives the autoimmune response. The evidence is strongest for rheumatoid arthritis, promising for MS and IBD, and preliminary for lupus and other conditions. Ozone should be viewed as a complement to standard autoimmune care, not a replacement. Work with both your autoimmune specialist and your ozone practitioner to develop a coordinated treatment plan.
References
- Bocci V, Valacchi G. Nrf2 activation as target to implement therapeutic treatments. Frontiers in Chemistry. 2015;3:4. doi:10.3389/fchem.2015.00004
- Leon Fernandez OS, Viebahn-Haensler R, Cabreja GL, et al. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. European Journal of Pharmacology. 2016;789:313-318. doi:10.1016/j.ejphar.2016.07.031
- Delgado-Roche L, Riera-Romo M, Mesta F, et al. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. European Journal of Pharmacology. 2017;811:148-154. doi:10.1016/j.ejphar.2017.06.017
- Menendez S, Cepero J, Borrego L. Ozone therapy in cancer treatment: State of the art. Ozone: Science & Engineering. 2008;30(6):398-404. doi:10.1080/01919510802473724
- Bocci V. Ozone: A New Medical Drug. 2nd ed. Springer; 2011. doi:10.1007/978-90-481-9234-2
- Zaky S, El-Badawy A, Ahmed E, et al. Ozone therapy as an adjuvant for conventional therapy in the treatment of chronic plaque psoriasis. Journal of the Egyptian Women’s Dermatologic Society. 2019;16(1):40-46.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
